Y-MABS THERAPEUTICS INC. - COMMON STOCK
6.0000
04-فبراير-25 14:52:28
15 متأخرة بدقائق
الأسهم
+0.2000
+3.45%
نطاق اليوم
5.7500 - 6.0700
ISIN
N/A
المصدر
NASDAQ
-
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
26 مايو 2023 08:00:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
26 مايو 2023 08:00:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
23 مايو 2023 08:00:00 بحسب Nasdaq GlobeNewswire
-
08 مايو 2023 15:01:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
28 أبريل 2023 08:00:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs Announces Presentation of Naxitamab data at AACR
18 أبريل 2023 08:00:02 بحسب Nasdaq GlobeNewswire
-
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
05 أبريل 2023 08:00:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
30 مارس 2023 15:01:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
21 مارس 2023 15:01:00 بحسب Nasdaq GlobeNewswire
-
02 فبراير 2023 08:00:00 بحسب Nasdaq GlobeNewswire
-
04 يناير 2023 15:01:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 يناير 2023 08:00:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
21 ديسمبر 2022 08:00:00 بحسب Nasdaq GlobeNewswire
-
16 ديسمبر 2022 15:01:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs Announces Pipeline Update
14 ديسمبر 2022 08:00:01 بحسب Nasdaq GlobeNewswire
-
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
08 ديسمبر 2022 08:00:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs to Host Annual Research and Development Day in New York
06 ديسمبر 2022 08:00:01 بحسب Nasdaq GlobeNewswire
-
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application
01 ديسمبر 2022 16:34:16 بحسب Nasdaq GlobeNewswire
-
Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
07 نوفمبر 2022 15:01:00 بحسب Nasdaq GlobeNewswire
-
Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022
02 نوفمبر 2022 15:01:00 بحسب Nasdaq GlobeNewswire